ORKA

SEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 3

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,884

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.38 to $95.19, inclusive.

SEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 2

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 239,147

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.29 to $94.26, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0000907654-26-000069 · form4.xml · nonDerivative · entry 1

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 241,384

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000066 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,312

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

SEC source: 0000907654-26-000066 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,011

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,899

F6 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000063 · form4.xml · derivative · entry 8

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 175,492

Underlying: Common Stock · 3,500 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000063 · form4.xml · derivative · entry 7

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 204,063

Underlying: Common Stock · 3,500 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 6

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,718

F6 · kind: These sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 5

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,665

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.29 to $70.79, inclusive.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 4

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 33,965

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $69.83, inclusive.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 3

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 39,029

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.97 to $68.96, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,665

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000063 · form4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,165

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 288 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.

SEC source: 0000907654-26-000062 · form4.xml · nonDerivative · entry 1

Klein Lawrence Otto · CIK 0001762583 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 925,580

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000061 · form4.xml · nonDerivative · entry 1

Sandler Laura Lee · CIK 0002075401 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 236,384

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000060 · form4.xml · nonDerivative · entry 1

Quinlan Paul T · CIK 0001333277 · General Counsel

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,034

F1 · kind: The reported sales were effected pursuant to Oruka Therapeutics, Inc.'s automatic, non-discretionary, sell-to-cover procedure to satisfy tax withholding obligations arising in connection with the vesting of restricted stock units.

SEC source: 0000907654-26-000054 · form4.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,743

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.50, inclusive.

SEC source: 0000907654-26-000064 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 62,708

Underlying: Common Stock · 1,459 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000064 · form4.xml · derivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 8,000 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,294

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.07 to $70.86, inclusive.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,554

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $70.06, inclusive.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,894

F2 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.87 to $68.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,753

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000064 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,294

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 888 shares acquired under the Oruka Therapeutics, Inc. stock purchase plan on June 8, 2026.

SEC source: 0000907654-26-000054 · form4.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,326

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.65, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

SEC source: 0000907654-26-000052 · form4.xml · derivative · entry 1

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,136

Underlying: Common Stock · 9,136 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

SEC source: 0000907654-26-000051 · form4.xml · derivative · entry 1

Kulkarni Samarth · CIK 0001682019 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,136

Underlying: Common Stock · 9,136 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

SEC source: 0000907654-26-000050 · form4.xml · derivative · entry 1

Martin Christopher Nathan · CIK 0002097992 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,136

Underlying: Common Stock · 9,136 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

SEC source: 0000907654-26-000049 · form4.xml · derivative · entry 1

BALL KRISTINE M · CIK 0001266163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,136

Underlying: Common Stock · 9,136 shares

Expires 2036-06-01

F1 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly from June 2, 2026.

SEC source: 0001104659-26-070135 · tm2616798-1_4seq1.xml · derivative · entry 1

Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner

Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner

Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director

Harwin Peter Evan · CIK 0001663607 · Director · 10% owner

Kiselak Tomas · CIK 0001830177 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By: Peter Harwin

Disclosed balance after: 9,136

Underlying: Common Stock · 9,136 shares

Expires 2036-06-01

F1 · derivative.exercise_date: This option represents a right to purchase 9,136 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2026, subject to the recipient's continued service to the Issuer.

F2 · ownership.direct: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest III L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

SEC source: 0000907654-26-000043 · form4.xml · derivative · entry 9

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,833

Underlying: Common Stock · 11,667 shares

Expires 2035-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/12 of the shares underlying the option monthly from June 2, 2025.

SEC source: 0000907654-26-000043 · form4.xml · derivative · entry 8

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,952

Underlying: Common Stock · 11,904 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 25% of the shares underlying the option on April 3, 2025, and as to 1/48 of the shares underlying the option monthly thereafter.

SEC source: 0000907654-26-000043 · form4.xml · derivative · entry 7

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,737

Underlying: Common Stock · 38,689 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vests as to 25% of the shares underlying the option on March 1, 2025, and as to 1/48 of the shares underlying the option monthly thereafter.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 6

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 73,743

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.71 to $60.31, inclusive.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 5

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,978

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.71 to $59.70, inclusive.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 4

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,425

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 19, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.71 to $58.70, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 3

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,743

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 2

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 167,076

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000043 · form4.xml · nonDerivative · entry 1

Dambkowski Carl · CIK 0001983476 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 155,172

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000041 · form4.xml · derivative · entry 8

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,167

Underlying: Common Stock · 5,833 shares

Expires 2036-01-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.

SEC source: 0000907654-26-000041 · form4.xml · derivative · entry 7

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,000

Underlying: Common Stock · 2,000 shares

Expires 2035-01-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option vests as to 1/48 of the underlying shares monthly from January 1, 2025.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 6

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,406

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.82 to $61.76, inclusive.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 5

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,106

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.78 to $60.72, inclusive.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 4

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,906

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.76 to $59.75, inclusive.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 3

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,506

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on February 11, 2026.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.72 to $58.71, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 2

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000041 · form4.xml · nonDerivative · entry 1

Agarwal Arjun · CIK 0002033974 · Senior Vice President, Finance

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,863

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000907654-26-000039 · form4.xml · derivative · entry 7

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 178,992

Underlying: Common Stock · 3,500 shares

Expires 2034-07-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.

SEC source: 0000907654-26-000039 · form4.xml · derivative · entry 6

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 207,563

Underlying: Common Stock · 3,500 shares

Expires 2034-05-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.